The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://stevequsy812585.ssnblog.com/37620774/retatrutide-vs-tirzepatide-a-comparative-analysis